Task Force Update Agenda

• Membership
• Revised Charges
• Initial Recommendations
• Remaining Work
# Task Force Roster

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Lane (Co-Chair)</td>
<td>Sutter Health</td>
</tr>
<tr>
<td>Leslie Kelly Hall (Co-Chair)</td>
<td>Engaging Patient Strategy</td>
</tr>
<tr>
<td>Ricky Bloomfield</td>
<td>Apple</td>
</tr>
<tr>
<td>Hans Buitendijk</td>
<td>Cerner</td>
</tr>
<tr>
<td>Grace Cordovano</td>
<td>Enlightening Results</td>
</tr>
<tr>
<td>Jim Jirjis</td>
<td>HCA Healthcare</td>
</tr>
<tr>
<td>Ken Kawamoto</td>
<td>University of Utah Health</td>
</tr>
<tr>
<td>Leslie Lenert</td>
<td>Medical University of South Carolina</td>
</tr>
<tr>
<td>Clement McDonald</td>
<td>National Library of Medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Miri</td>
<td>The University of Texas at Austin, Dell Medical School and UT Health Austin</td>
</tr>
<tr>
<td>Brett Oliver</td>
<td>Baptist Health</td>
</tr>
<tr>
<td>Mark Savage</td>
<td>University of California's Center for Digital Health Innovation</td>
</tr>
<tr>
<td>Michelle Schreiber</td>
<td>CMS</td>
</tr>
<tr>
<td>Sasha TerMaat</td>
<td>Epic</td>
</tr>
<tr>
<td>Andrew Truscott</td>
<td>Accenture</td>
</tr>
<tr>
<td>Sheryl Turney</td>
<td>Anthem, Inc.</td>
</tr>
<tr>
<td>Daniel Vreeman</td>
<td>RTI International</td>
</tr>
<tr>
<td>Denise Webb</td>
<td>Indiana Hemophilia and Thrombosis Center</td>
</tr>
</tbody>
</table>
Completed Phase 1 Meetings

- February 2, 2021
- February 9, 2021
- February 16, 2021
- February 23, 2021
- March 2, 2021
- March 9, 2021
USCDI Version Update Process

2020
- Submission & Review Period - v2
  - ONC v2 Draft Prep
  - HITAC v2 Public Comment v2
  - ONC Review/Approval

USCDI v1 Final

October

January

April

July

USCDI v2 Draft

USCDI v2 Final

Considered for 2021 SVAP

2021
- Submission & Review Period - v3
  - ONC v3 Draft Prep
  - HITAC v3 Public Comment v3
  - ONC Review/Approval

USCDI v3 Draft

Considered for 2022 SVAP

2022
- Submission & Review Period - v4
  - ONC v4 Draft Prep
  - HITAC v4 Public Comment v4
  - ONC Review/Approval

USCDI v4 Final
Task Force Charge

Overarching charge:

Review and provide recommendations on the Draft USCDI Version 2 content and process

Specific charges:

1. Evaluate Draft USCDI v2 and provide HITAC with recommendations for:
   1a - Data classes and elements from USCDI v1 including applicable standards version updates
   1b - New data classes and elements from Draft USCDI v2 including applicable standards
   1c - Level 2 data classes and elements not included in Draft USCDI v2

   Due: April 15, 2021

2. Evaluate the USCDI expansion process and provide HITAC with recommendations for:
   2a - ONDEC submission system improvements
   2b - Evaluation criteria and process used to assign levels to submitted data classes and elements
   2c - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

   Due: September 9, 2021

3. Recommend ONC priorities for USCDI version 3 submission cycle

   Due: September 9, 2021
USCDI TF Initial Recommendations
Task 1a – Evaluate v1 Data Elements and Applicable Vocabulary Standards

• Support for updating all applicable vocabulary standards to latest versions, as of Final USCDI v2 publication (e.g., LOINC 2.70 June 2021)
• Support for reclassifying 3 Clinical Notes data elements
• Clarify scope and definitions of Diagnostic Imaging Class with examples
• Clarify scope and definitions of Assessment and Plan of Treatment Class with examples
Draft USCDI version 2
Reclassified Clinical Note Data Elements

- Clinical Notes
  - Consultation Note
  - Discharge Summary Note
  - History & Physical
  - Procedure Note
  - Progress Note
  - Diagnostic Imaging Narrative
  - Laboratory Report Narrative
  - Pathology Report Narrative

- Diagnostic Imaging – New Class
  - Diagnostic Imaging Narrative

- Laboratory – Existing Class
  - Laboratory Report Narrative
  - Pathology Report Narrative
USCDI TF Initial Recommendations
Task 1b – Evaluate New Data Elements in Draft v2

• Incorporate Diagnostic Imaging Narrative element into Diagnostic Imaging Report
• Clarify scope of Diagnostic Imaging Report (to include narrative)
• Incorporate Laboratory and Pathology Report Narratives into Laboratory Values/Results
• Clarify scope of Laboratory Values/Results (to include narrative)
• Change Provider Name and Identifier to Care Team Member Name and Identifier
• Clarify scope of Encounter Time (e.g., scheduled time, arrival time, start/end time, duration, current, future)
Remaining Work

• Refine Tasks 1a, 1b Recommendations

• Complete Task 1c Recommendations

• Phase 2 Planning
  • Task 2 - Evaluate the USCDI expansion process
  • Task 3 - Recommend ONC priorities for USCDI version 3 submission cycle
Further Discussion: HITAC Guidance Needed

• Discussions continue around scope and alignment of USCDI regulatory efforts and stakeholder needs.

• Stakeholders present different and sometimes competing needs.
  • Data-Underserved (patients, public health, FQHC)
  • Providers
  • Payers (CMS)
  • Regulatory bodies
  • Quality/Safety
Remaining Phase 1 Meetings

• March 16, 2021  10:30a - 12:00p ET
• March 23, 2021  10:30a - 12:00p ET
• April  6, 2021  10:30a - 12:00p ET
• April 13, 2021  10:30a - 12:00p ET
Questions?